[
  {
    "ts": null,
    "headline": "Morgan Stanley Files for Bitcoin and Solana Trusts in ETF Push",
    "summary": "The bank submitted filings for crypto trusts holding Bitcoin and Solana, including a Solana staking component.",
    "url": "https://finnhub.io/api/news?id=aa9ce39169ce0ef9d4562f6f26e444ab18acc01213004436ed9e967e3ce12ba9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767719756,
      "headline": "Morgan Stanley Files for Bitcoin and Solana Trusts in ETF Push",
      "id": 138001886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "The bank submitted filings for crypto trusts holding Bitcoin and Solana, including a Solana staking component.",
      "url": "https://finnhub.io/api/news?id=aa9ce39169ce0ef9d4562f6f26e444ab18acc01213004436ed9e967e3ce12ba9"
    }
  },
  {
    "ts": null,
    "headline": "Expect Broadening of Earnings Growth in 2026: JPM's Sundar",
    "summary": "Sitara Sundar, Head of Alternative Investment Strategy at JPMorgan Private Bank, says the AI capital expenditure cycle will continue in 2026 and expects a broadening of earnings growth. She speaks to Bloomberg's Vonnie Quinn on 'Bloomberg Brief.'",
    "url": "https://finnhub.io/api/news?id=36f98d02ff9b5d5c808ae352066f3992e14e21cd353d55e594c9fed878563d16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767717223,
      "headline": "Expect Broadening of Earnings Growth in 2026: JPM's Sundar",
      "id": 138001887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Sitara Sundar, Head of Alternative Investment Strategy at JPMorgan Private Bank, says the AI capital expenditure cycle will continue in 2026 and expects a broadening of earnings growth. She speaks to Bloomberg's Vonnie Quinn on 'Bloomberg Brief.'",
      "url": "https://finnhub.io/api/news?id=36f98d02ff9b5d5c808ae352066f3992e14e21cd353d55e594c9fed878563d16"
    }
  },
  {
    "ts": null,
    "headline": "Helping Los Angeles Heal: JPMorganChase Marks A Year of Support for Wildfire Recovery",
    "summary": "LOS ANGELES, January 06, 2026--Today, JPMorganChase announced its continued investment in Los Angeles’s wildfire recovery efforts, reaffirming its ongoing support to building resilience and hope for Angelenos.",
    "url": "https://finnhub.io/api/news?id=d40cb8b65804967d31d735c5da942294f8912ff7cb90ca28b01a3d740dbf2bdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767716760,
      "headline": "Helping Los Angeles Heal: JPMorganChase Marks A Year of Support for Wildfire Recovery",
      "id": 138001888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "LOS ANGELES, January 06, 2026--Today, JPMorganChase announced its continued investment in Los Angeles’s wildfire recovery efforts, reaffirming its ongoing support to building resilience and hope for Angelenos.",
      "url": "https://finnhub.io/api/news?id=d40cb8b65804967d31d735c5da942294f8912ff7cb90ca28b01a3d740dbf2bdf"
    }
  },
  {
    "ts": null,
    "headline": "Acadia Healthcare to Participate in 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "FRANKLIN, Tenn., January 06, 2026--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, January 12-15, 2026, in San Francisco, California.",
    "url": "https://finnhub.io/api/news?id=b0f5d8f9457e8c480092433261b9b81426be7726375266328435718472434276",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767715200,
      "headline": "Acadia Healthcare to Participate in 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138001889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "FRANKLIN, Tenn., January 06, 2026--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, January 12-15, 2026, in San Francisco, California.",
      "url": "https://finnhub.io/api/news?id=b0f5d8f9457e8c480092433261b9b81426be7726375266328435718472434276"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Chase & Co. (JPM) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "JPMorgan Chase & Co. (JPM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=041f7b6762a073086c73332a5553b81fb975216ddfa861d23a610a1b08a1842c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767711603,
      "headline": "JPMorgan Chase & Co. (JPM) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 138001890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan Chase & Co. (JPM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=041f7b6762a073086c73332a5553b81fb975216ddfa861d23a610a1b08a1842c"
    }
  },
  {
    "ts": null,
    "headline": "Global M&A Engine Revs Up: How to Play Morgan Stanley Stock?",
    "summary": "MS rides a 41% global M&A surge and wealth pivot to boost earnings, but rising costs and valuation raise flags. Is the stock a buy for 2026? Let's find out.",
    "url": "https://finnhub.io/api/news?id=3193eb2d63168fbd10ff53ab90ff72c89e579884ec1eb5df9c744fcceafa3e88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767711240,
      "headline": "Global M&A Engine Revs Up: How to Play Morgan Stanley Stock?",
      "id": 138001891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "MS rides a 41% global M&A surge and wealth pivot to boost earnings, but rising costs and valuation raise flags. Is the stock a buy for 2026? Let's find out.",
      "url": "https://finnhub.io/api/news?id=3193eb2d63168fbd10ff53ab90ff72c89e579884ec1eb5df9c744fcceafa3e88"
    }
  },
  {
    "ts": null,
    "headline": "New to Investing? This 1 Finance Stock Could Be the Perfect Starting Point",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.",
    "url": "https://finnhub.io/api/news?id=df3808da9b968586b4c09c581c1af903288d279a01adde18f8e66636be68c97b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767709803,
      "headline": "New to Investing? This 1 Finance Stock Could Be the Perfect Starting Point",
      "id": 138001892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.",
      "url": "https://finnhub.io/api/news?id=df3808da9b968586b4c09c581c1af903288d279a01adde18f8e66636be68c97b"
    }
  },
  {
    "ts": null,
    "headline": "Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay",
    "url": "https://finnhub.io/api/news?id=478ee73a6f4bd1ff83bfca6afab24836e68417242170461dcd48680ec8b63dde",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767709800,
      "headline": "Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay",
      "url": "https://finnhub.io/api/news?id=478ee73a6f4bd1ff83bfca6afab24836e68417242170461dcd48680ec8b63dde"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News for Jan 6, 2026",
    "summary": "Wall Street closed sharply higher on Monday, led by energy and financial stocks.",
    "url": "https://finnhub.io/api/news?id=3e6ec9b674d6fdc648691efb103e7ab40d37b84120baa4f6fb723ced99b3d570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767709440,
      "headline": "Stock Market News for Jan 6, 2026",
      "id": 138001893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Wall Street closed sharply higher on Monday, led by energy and financial stocks.",
      "url": "https://finnhub.io/api/news?id=3e6ec9b674d6fdc648691efb103e7ab40d37b84120baa4f6fb723ced99b3d570"
    }
  },
  {
    "ts": null,
    "headline": "Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration",
    "summary": "Management to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceNESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprie",
    "url": "https://finnhub.io/api/news?id=f595ea3c92a296e0d37f22fc1a1792b7c63b6158304b6f0aeab17ef196b73ec7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708000,
      "headline": "Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration",
      "id": 138000112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Management to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceNESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprie",
      "url": "https://finnhub.io/api/news?id=f595ea3c92a296e0d37f22fc1a1792b7c63b6158304b6f0aeab17ef196b73ec7"
    }
  },
  {
    "ts": null,
    "headline": "Actio Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "SAN DIEGO, January 06, 2026--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced that David Goldstein, Ph.D., co-founder and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 2:00 p.m. PT in San Francisco, California.",
    "url": "https://finnhub.io/api/news?id=08af4c74671b58f4a38e5aa3a06d456e43ee4625e817146d30703d467db3d8d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708000,
      "headline": "Actio Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SAN DIEGO, January 06, 2026--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced that David Goldstein, Ph.D., co-founder and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 2:00 p.m. PT in San Francisco, California.",
      "url": "https://finnhub.io/api/news?id=08af4c74671b58f4a38e5aa3a06d456e43ee4625e817146d30703d467db3d8d2"
    }
  },
  {
    "ts": null,
    "headline": "GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week",
    "summary": "ATLANTA, GA - January 6, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company advancing innovative immunotherapies and vaccines for cancer and infectious diseases, today announced that senior management will ...",
    "url": "https://finnhub.io/api/news?id=885c1290522c796bda2a6ac583f2a48ee48ceeb473a9be986269843e831f296e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708000,
      "headline": "GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week",
      "id": 138000110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "ATLANTA, GA - January 6, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company advancing innovative immunotherapies and vaccines for cancer and infectious diseases, today announced that senior management will ...",
      "url": "https://finnhub.io/api/news?id=885c1290522c796bda2a6ac583f2a48ee48ceeb473a9be986269843e831f296e"
    }
  },
  {
    "ts": null,
    "headline": "Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026",
    "summary": "SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., January 06, 2026--Kardigan™, a heart health company modernizing cardiovascular (CV) drug development, today announced its upcoming corporate presentation at the 2026 J.P. Morgan Healthcare Conference (\"JPM 2026\") on Monday, January 12 at 8:00 a.m. PT. The presentation marks an important milestone for Kardigan as it enters 2026 with multiple clinical data readouts expected across its late-stage portfolio of personalized CV medicines in specific types",
    "url": "https://finnhub.io/api/news?id=cffaa9afce0568627c6383cf5941dfce2a4d271d8757442c99513433b3f624f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708000,
      "headline": "Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026",
      "id": 138000109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., January 06, 2026--Kardigan™, a heart health company modernizing cardiovascular (CV) drug development, today announced its upcoming corporate presentation at the 2026 J.P. Morgan Healthcare Conference (\"JPM 2026\") on Monday, January 12 at 8:00 a.m. PT. The presentation marks an important milestone for Kardigan as it enters 2026 with multiple clinical data readouts expected across its late-stage portfolio of personalized CV medicines in specific types",
      "url": "https://finnhub.io/api/news?id=cffaa9afce0568627c6383cf5941dfce2a4d271d8757442c99513433b3f624f8"
    }
  },
  {
    "ts": null,
    "headline": "Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "CHICAGO, January 06, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California.",
    "url": "https://finnhub.io/api/news?id=19dee59d43058aaf7a7b617976a234b24279c84ca2f4dfcfeb604c05fdcb1fe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767706200,
      "headline": "Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000114,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "CHICAGO, January 06, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California.",
      "url": "https://finnhub.io/api/news?id=19dee59d43058aaf7a7b617976a234b24279c84ca2f4dfcfeb604c05fdcb1fe5"
    }
  },
  {
    "ts": null,
    "headline": "Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026",
    "summary": "CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Cor",
    "url": "https://finnhub.io/api/news?id=8a995e73c6c7b8c9b5e5991fef4910ec0fe437ae03a36f741201c9c2cb9c86f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767706200,
      "headline": "Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026",
      "id": 138000113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Cor",
      "url": "https://finnhub.io/api/news?id=8a995e73c6c7b8c9b5e5991fef4910ec0fe437ae03a36f741201c9c2cb9c86f2"
    }
  },
  {
    "ts": null,
    "headline": "Jamie Dimon made $770 million last year, and 2026 could be even better for banks",
    "summary": "Easing rules and a rebound in dealmaking are reshaping the landscape for U.S. banks, with bigger profits likely ahead",
    "url": "https://finnhub.io/api/news?id=8a787b608c4c5b9af1b0fdbe26aeaff2a7b694cb3940ad23e779e4384a8ca9bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704973,
      "headline": "Jamie Dimon made $770 million last year, and 2026 could be even better for banks",
      "id": 138000115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Easing rules and a rebound in dealmaking are reshaping the landscape for U.S. banks, with bigger profits likely ahead",
      "url": "https://finnhub.io/api/news?id=8a787b608c4c5b9af1b0fdbe26aeaff2a7b694cb3940ad23e779e4384a8ca9bb"
    }
  },
  {
    "ts": null,
    "headline": "Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th",
    "summary": "SAN DIEGO, January 06, 2026--Candid Therapeutics, Inc. (\"Candid\"), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that Dr. Ken Song, Chairman, President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 a.m. PT, at The Westin St. Francis Hotel in San Francisco.",
    "url": "https://finnhub.io/api/news?id=86b1f6ec46384348524c2b3297125fe90401b55f0a047a6fbf11885f5f10e79b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th",
      "id": 138000124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SAN DIEGO, January 06, 2026--Candid Therapeutics, Inc. (\"Candid\"), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that Dr. Ken Song, Chairman, President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 a.m. PT, at The Westin St. Francis Hotel in San Francisco.",
      "url": "https://finnhub.io/api/news?id=86b1f6ec46384348524c2b3297125fe90401b55f0a047a6fbf11885f5f10e79b"
    }
  },
  {
    "ts": null,
    "headline": "Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California. Management will present on Tuesday, January 13, 2026, at 1:30 pm Pacific Time and will also particip",
    "url": "https://finnhub.io/api/news?id=8142324865bd16a9ac582e315d31fceab4c47e19e43d56c4db6778d4d28fde05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California. Management will present on Tuesday, January 13, 2026, at 1:30 pm Pacific Time and will also particip",
      "url": "https://finnhub.io/api/news?id=8142324865bd16a9ac582e315d31fceab4c47e19e43d56c4db6778d4d28fde05"
    }
  },
  {
    "ts": null,
    "headline": "Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "BOTHELL, Wash., January 06, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.",
    "url": "https://finnhub.io/api/news?id=49ba0b09ae3e664fcb65edb2eb4b0f4dc5d5ecfe5c7e04a78e1ac3ad2e81fd1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "BOTHELL, Wash., January 06, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.",
      "url": "https://finnhub.io/api/news?id=49ba0b09ae3e664fcb65edb2eb4b0f4dc5d5ecfe5c7e04a78e1ac3ad2e81fd1e"
    }
  },
  {
    "ts": null,
    "headline": "SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company’s CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 7:30 a.m. PT/10:30 a.m. ET in San Francisco, CA. A live webcast of the presentation will be available in the “Inves",
    "url": "https://finnhub.io/api/news?id=04f906ac9ae5f0f2da6bed6d874981f64a7f0b3bfbd4a60d5df17cbe3d3227b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company’s CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 7:30 a.m. PT/10:30 a.m. ET in San Francisco, CA. A live webcast of the presentation will be available in the “Inves",
      "url": "https://finnhub.io/api/news?id=04f906ac9ae5f0f2da6bed6d874981f64a7f0b3bfbd4a60d5df17cbe3d3227b6"
    }
  },
  {
    "ts": null,
    "headline": "Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 a.m. PT/11:15 a.m. ET. A live webcast will be available on the Investors & Media page of Cogen",
    "url": "https://finnhub.io/api/news?id=3e04bf93cff4e4e17008a75c30ace6273b53c87f230854cdc1c14c418c3fdb1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 a.m. PT/11:15 a.m. ET. A live webcast will be available on the Investors & Media page of Cogen",
      "url": "https://finnhub.io/api/news?id=3e04bf93cff4e4e17008a75c30ace6273b53c87f230854cdc1c14c418c3fdb1e"
    }
  },
  {
    "ts": null,
    "headline": "Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
    "url": "https://finnhub.io/api/news?id=ab5cabd795690d0b2f00569404522eb5854b2eb154eb87c6389c967e692a18a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
      "url": "https://finnhub.io/api/news?id=ab5cabd795690d0b2f00569404522eb5854b2eb154eb87c6389c967e692a18a7"
    }
  },
  {
    "ts": null,
    "headline": "Seismic Therapeutic Announces Updated Presentation Time at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc., the machine learning immunology company, today announced an update to its presentation scheduled at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Jo Viney, Ph.D., Founder, President and Chief Executive Officer, will now present a company overview on Monday, January 12, 2026, at 1:30 p.m. PT. Members of the Seismic management team will also be available for one-on-one meetings. About S",
    "url": "https://finnhub.io/api/news?id=198f3706ba330e19baa08fa8e5ef229ac0d6aa7ac3cb81db05c49151229cbe91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Seismic Therapeutic Announces Updated Presentation Time at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc., the machine learning immunology company, today announced an update to its presentation scheduled at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Jo Viney, Ph.D., Founder, President and Chief Executive Officer, will now present a company overview on Monday, January 12, 2026, at 1:30 p.m. PT. Members of the Seismic management team will also be available for one-on-one meetings. About S",
      "url": "https://finnhub.io/api/news?id=198f3706ba330e19baa08fa8e5ef229ac0d6aa7ac3cb81db05c49151229cbe91"
    }
  },
  {
    "ts": null,
    "headline": "NodThera Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced that Chris Guiffre, J.D., M.B.A., Chief Financial Officer of NodThera, will present at the 44th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2026, in San Francisco, CA. Details of the presentation are as follows: 44th Annual J.P. Morgan Healthcare Conferenc",
    "url": "https://finnhub.io/api/news?id=554378d3296b897e61208800544cc6062026d0da92b2f774a594f4dc5127b072",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "NodThera Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 138000117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced that Chris Guiffre, J.D., M.B.A., Chief Financial Officer of NodThera, will present at the 44th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2026, in San Francisco, CA. Details of the presentation are as follows: 44th Annual J.P. Morgan Healthcare Conferenc",
      "url": "https://finnhub.io/api/news?id=554378d3296b897e61208800544cc6062026d0da92b2f774a594f4dc5127b072"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference",
    "summary": "WALTHAM, Mass., January 06, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET).",
    "url": "https://finnhub.io/api/news?id=975fab526b7cdc78b0d006a934cd390344fc9a7ed399f69d9c27edcc9ff7af5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference",
      "id": 138000116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., January 06, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET).",
      "url": "https://finnhub.io/api/news?id=975fab526b7cdc78b0d006a934cd390344fc9a7ed399f69d9c27edcc9ff7af5b"
    }
  },
  {
    "ts": null,
    "headline": "Passive Income Dividend Giants Dominate JP Morgan’s 2026 Energy Top Picks",
    "summary": "J.P. Morgan’s highest-yielding top pick energy stocks for 2026 have secular growth drivers, robust balance sheets, and exposure to transformative trends.",
    "url": "https://finnhub.io/api/news?id=bbe5493353740b74983563500bb5b84a920d75f2238d51d89c393e96bc0f3f74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767703331,
      "headline": "Passive Income Dividend Giants Dominate JP Morgan’s 2026 Energy Top Picks",
      "id": 138000125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "J.P. Morgan’s highest-yielding top pick energy stocks for 2026 have secular growth drivers, robust balance sheets, and exposure to transformative trends.",
      "url": "https://finnhub.io/api/news?id=bbe5493353740b74983563500bb5b84a920d75f2238d51d89c393e96bc0f3f74"
    }
  },
  {
    "ts": null,
    "headline": "Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available for replay until February 14, 2026. Ab",
    "url": "https://finnhub.io/api/news?id=b4695366b83d2060fd6056b6434975b31198b2dc4abf90255ca5bb6b6901f501",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767702600,
      "headline": "Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 137999672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available for replay until February 14, 2026. Ab",
      "url": "https://finnhub.io/api/news?id=b4695366b83d2060fd6056b6434975b31198b2dc4abf90255ca5bb6b6901f501"
    }
  },
  {
    "ts": null,
    "headline": "ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company\"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 20",
    "url": "https://finnhub.io/api/news?id=43a7ab3da25c71324e6ad71d5c55109e313137f95928b8418bb18d1412cfb5de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767702600,
      "headline": "ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 137999671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company\"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 20",
      "url": "https://finnhub.io/api/news?id=43a7ab3da25c71324e6ad71d5c55109e313137f95928b8418bb18d1412cfb5de"
    }
  },
  {
    "ts": null,
    "headline": "Did JPMorgan's New Advisory and Blockchain Push Just Shift JPMorgan Chase's (JPM) Investment Narrative?",
    "summary": "In early January 2026, JPMorgan Chase expanded its innovation push by launching a Special Advisory Services unit for top clients and accelerating its blockchain and digital asset efforts, including bringing JPM Coin onto a public blockchain. This combination of high-touch advisory around themes like AI and cybersecurity with on-chain finance initiatives underlines JPMorgan’s attempt to embed itself more deeply in clients’ future-facing financial and technology decisions. We’ll now examine...",
    "url": "https://finnhub.io/api/news?id=93b01b8be95110a286cdc447a6a8a399b46aec1d259cbefde9f1b657e480e19b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767701397,
      "headline": "Did JPMorgan's New Advisory and Blockchain Push Just Shift JPMorgan Chase's (JPM) Investment Narrative?",
      "id": 137999673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "In early January 2026, JPMorgan Chase expanded its innovation push by launching a Special Advisory Services unit for top clients and accelerating its blockchain and digital asset efforts, including bringing JPM Coin onto a public blockchain. This combination of high-touch advisory around themes like AI and cybersecurity with on-chain finance initiatives underlines JPMorgan’s attempt to embed itself more deeply in clients’ future-facing financial and technology decisions. We’ll now examine...",
      "url": "https://finnhub.io/api/news?id=93b01b8be95110a286cdc447a6a8a399b46aec1d259cbefde9f1b657e480e19b"
    }
  },
  {
    "ts": null,
    "headline": "Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference",
    "summary": "Lead program ALE1 for hypophosphatasia (HPP) progressing through the clinic with a Ph1/2a study currently ongoing in healthy volunteers; HPP patients expected to be dosed in H1 2026 Second therapeutic candidate for large unmet indication under development LEIDEN, The Netherlands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alesta Therapeutics, a biotechnology company focused on developing transformative small-molecule therapies for underserved diseases, provided a corporate and clinical update in advance",
    "url": "https://finnhub.io/api/news?id=a5b9cdde29e447acf324bd69a5017d4942e82331797a9c5a75de11ce87ed5259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767700800,
      "headline": "Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference",
      "id": 137999353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Lead program ALE1 for hypophosphatasia (HPP) progressing through the clinic with a Ph1/2a study currently ongoing in healthy volunteers; HPP patients expected to be dosed in H1 2026 Second therapeutic candidate for large unmet indication under development LEIDEN, The Netherlands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alesta Therapeutics, a biotechnology company focused on developing transformative small-molecule therapies for underserved diseases, provided a corporate and clinical update in advance",
      "url": "https://finnhub.io/api/news?id=a5b9cdde29e447acf324bd69a5017d4942e82331797a9c5a75de11ce87ed5259"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13",
    "summary": "WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the C",
    "url": "https://finnhub.io/api/news?id=6126b81703d83f068aa51e67dbf162f200fa3a9e74cfc6eed52f836c37adc09c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767700800,
      "headline": "Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13",
      "id": 137999352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the C",
      "url": "https://finnhub.io/api/news?id=6126b81703d83f068aa51e67dbf162f200fa3a9e74cfc6eed52f836c37adc09c"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Nvidia, AMD, JPMorgan, Zeta Global, Vistra, Microchip, and More",
    "summary": "Nvidia CEO Jensen Huang says the chip maker’s next big AI graphics processing unit, Vera Rubin, is in ‘full production,’ while Vistra shares rise after the electricity and power-generation company reaches a deal to buy Cogentrix Energy.",
    "url": "https://finnhub.io/api/news?id=7cc76fcddb9f68e7c424cb21dec0ed2b72a156916f477e53fbc98903af8dcb26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767695700,
      "headline": "These Stocks Are Moving the Most Today: Nvidia, AMD, JPMorgan, Zeta Global, Vistra, Microchip, and More",
      "id": 137999308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Nvidia CEO Jensen Huang says the chip maker’s next big AI graphics processing unit, Vera Rubin, is in ‘full production,’ while Vistra shares rise after the electricity and power-generation company reaches a deal to buy Cogentrix Energy.",
      "url": "https://finnhub.io/api/news?id=7cc76fcddb9f68e7c424cb21dec0ed2b72a156916f477e53fbc98903af8dcb26"
    }
  },
  {
    "ts": null,
    "headline": "Claritev Corporation to Present at J.P. Morgan Healthcare Conference",
    "summary": "MCLEAN, Va., January 06, 2026--Claritev Corporation (\"Claritev\" or the \"Company\") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will be presenting on Thursday, January 15, 2026 at 7:30 a.m. PT. A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev’s",
    "url": "https://finnhub.io/api/news?id=c9b247b871d33fb50c828a598c8f2fc8aa10069dbc3e5d56b165f9a2af3e8ee3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767693600,
      "headline": "Claritev Corporation to Present at J.P. Morgan Healthcare Conference",
      "id": 137998714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "MCLEAN, Va., January 06, 2026--Claritev Corporation (\"Claritev\" or the \"Company\") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will be presenting on Thursday, January 15, 2026 at 7:30 a.m. PT. A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev’s",
      "url": "https://finnhub.io/api/news?id=c9b247b871d33fb50c828a598c8f2fc8aa10069dbc3e5d56b165f9a2af3e8ee3"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Favors 'Diversified Approach' to 2026 AI Trade",
    "summary": "JPMorgan strategist Hugh Gimber says the AI trade is \"intact\" but favors a \"more diversified\" investment approach which includes Chinese technology firms. \"It's about spreading where you want to take your risk in portfolios,\" Gimber tells Bloomberg Television.",
    "url": "https://finnhub.io/api/news?id=4b0bd6162f1ab1228d4e0ed3087fa31b4baf717f1436519f6a3852a1b965314d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767693526,
      "headline": "JPMorgan Favors 'Diversified Approach' to 2026 AI Trade",
      "id": 137999355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan strategist Hugh Gimber says the AI trade is \"intact\" but favors a \"more diversified\" investment approach which includes Chinese technology firms. \"It's about spreading where you want to take your risk in portfolios,\" Gimber tells Bloomberg Television.",
      "url": "https://finnhub.io/api/news?id=4b0bd6162f1ab1228d4e0ed3087fa31b4baf717f1436519f6a3852a1b965314d"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan's Wiltz 'Bullish' in Capacity to Deliver IPOs in 2026",
    "summary": "A top JPMorgan's banker, EMEA co-head Mathieu Wiltz, said the US bank is 'bullish' in its capacity to deliver more IPOs this year. Despite the global headwinds, Matthieu Wiltz said the sentiment is 'positive' for 2026. He spoke exclusively with Bloomberg's Anna Edwards, Tom Mackenzie and Guy Johnson from Paris.",
    "url": "https://finnhub.io/api/news?id=d171fecb6389cd28f9ba1ac13b747c9b81c5c60f9691ece21c71afd13e264221",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767692265,
      "headline": "JPMorgan's Wiltz 'Bullish' in Capacity to Deliver IPOs in 2026",
      "id": 137999356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "A top JPMorgan's banker, EMEA co-head Mathieu Wiltz, said the US bank is 'bullish' in its capacity to deliver more IPOs this year. Despite the global headwinds, Matthieu Wiltz said the sentiment is 'positive' for 2026. He spoke exclusively with Bloomberg's Anna Edwards, Tom Mackenzie and Guy Johnson from Paris.",
      "url": "https://finnhub.io/api/news?id=d171fecb6389cd28f9ba1ac13b747c9b81c5c60f9691ece21c71afd13e264221"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan's Bharti on 2026 India IPO Outlook",
    "summary": "Abhinav Bharti, Head of India Equity Capital Markets at JPMorgan, shares his outlook for India's equity capital markets. He expects technology and consumer sectors to be the most active in raising funds this year. He spoke on Bloomberg's Insight with Haslinda Amin.",
    "url": "https://finnhub.io/api/news?id=4e2cce481be374e73643d06ec42f897ade45f3281fb8bb5720944dc1055adc81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767687974,
      "headline": "JPMorgan's Bharti on 2026 India IPO Outlook",
      "id": 137998715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Abhinav Bharti, Head of India Equity Capital Markets at JPMorgan, shares his outlook for India's equity capital markets. He expects technology and consumer sectors to be the most active in raising funds this year. He spoke on Bloomberg's Insight with Haslinda Amin.",
      "url": "https://finnhub.io/api/news?id=4e2cce481be374e73643d06ec42f897ade45f3281fb8bb5720944dc1055adc81"
    }
  },
  {
    "ts": null,
    "headline": "Maduro pleads not guilty, Nvidia's robotaxi play, JPMorgan's 'secret sauce' and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=06acfbc4ae926a040dd51f1cc94d398ca27ca2a92007faf0d370a9e70492b0f3",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767686851,
      "headline": "Maduro pleads not guilty, Nvidia's robotaxi play, JPMorgan's 'secret sauce' and more in Morning Squawk",
      "id": 138001438,
      "image": "https://image.cnbcfm.com/api/v1/image/108248413-17676467022026-01-05t205525z_137126114_rc20viatjymw_rtrmadp_0_usa-venezuela-maduro-new-york.jpeg?v=1767646767&w=1920&h=1080",
      "related": "JPM",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=06acfbc4ae926a040dd51f1cc94d398ca27ca2a92007faf0d370a9e70492b0f3"
    }
  },
  {
    "ts": null,
    "headline": "argenx to Present at 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl",
    "url": "https://finnhub.io/api/news?id=94873c13ead0f4efc8579e98ed98194ae190bf3dc6798f51c6e4dfb9a4c6d04f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767679200,
      "headline": "argenx to Present at 44th Annual J.P. Morgan Healthcare Conference",
      "id": 137997643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl",
      "url": "https://finnhub.io/api/news?id=94873c13ead0f4efc8579e98ed98194ae190bf3dc6798f51c6e4dfb9a4c6d04f"
    }
  },
  {
    "ts": null,
    "headline": "Colgate-Palmolive (CL) Remains Overweight as JPMorgan Sees Headwinds Easing in 2026",
    "summary": "Colgate-Palmolive Company (NYSE:CL) is included among the 13 Best January Dividend Stocks to Invest in. On December 18, JPMorgan raised its price target on Colgate-Palmolive Company (NYSE:CL) to $88 from $87 and kept an Overweight rating as part of its 2026 outlook. The firm said the setup heading into 2026 for beverages, household, and personal care […]",
    "url": "https://finnhub.io/api/news?id=72b1b5d9778be0a30fe9e3a0650a82db6c45b3750786fa1cd061d9ffe37e2a58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767668300,
      "headline": "Colgate-Palmolive (CL) Remains Overweight as JPMorgan Sees Headwinds Easing in 2026",
      "id": 137997644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Colgate-Palmolive Company (NYSE:CL) is included among the 13 Best January Dividend Stocks to Invest in. On December 18, JPMorgan raised its price target on Colgate-Palmolive Company (NYSE:CL) to $88 from $87 and kept an Overweight rating as part of its 2026 outlook. The firm said the setup heading into 2026 for beverages, household, and personal care […]",
      "url": "https://finnhub.io/api/news?id=72b1b5d9778be0a30fe9e3a0650a82db6c45b3750786fa1cd061d9ffe37e2a58"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan (JPM) Gets Fresh Price Target Bump as Barclays Stays Overweight on Big Banks",
    "summary": "JPMorgan Chase & Co. (NYSE:JPM) is included among the 13 Best January Dividend Stocks to Invest in. On January 5, Barclays raised its price target on JPMorgan Chase & Co. (NYSE: JPM) to $391 from $342 and maintained an Overweight rating on the stock. The move came as part of the firm’s broader 2026 outlook for […]",
    "url": "https://finnhub.io/api/news?id=f6cb3665f009fea8f892d5ee6e27c18f01351b8e731b911ca53dea0943cecf00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767666706,
      "headline": "JPMorgan (JPM) Gets Fresh Price Target Bump as Barclays Stays Overweight on Big Banks",
      "id": 137997645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "JPMorgan Chase & Co. (NYSE:JPM) is included among the 13 Best January Dividend Stocks to Invest in. On January 5, Barclays raised its price target on JPMorgan Chase & Co. (NYSE: JPM) to $391 from $342 and maintained an Overweight rating on the stock. The move came as part of the firm’s broader 2026 outlook for […]",
      "url": "https://finnhub.io/api/news?id=f6cb3665f009fea8f892d5ee6e27c18f01351b8e731b911ca53dea0943cecf00"
    }
  },
  {
    "ts": null,
    "headline": "My 10 Recommended Stocks For 2026",
    "summary": "My 2026 recommended stock portfolio has five US and five Brazilian stocks, targeting under-the-radar ideas and higher dividend yield. Check out the portfolio here.",
    "url": "https://finnhub.io/api/news?id=2063a80af72b6ad2cf390a0057c9c7b2cc6af101d11c0cc129278e56549ad4f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767661999,
      "headline": "My 10 Recommended Stocks For 2026",
      "id": 137996815,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2219445955/image_2219445955.jpg?io=getty-c-w1536",
      "related": "JPM",
      "source": "SeekingAlpha",
      "summary": "My 2026 recommended stock portfolio has five US and five Brazilian stocks, targeting under-the-radar ideas and higher dividend yield. Check out the portfolio here.",
      "url": "https://finnhub.io/api/news?id=2063a80af72b6ad2cf390a0057c9c7b2cc6af101d11c0cc129278e56549ad4f9"
    }
  },
  {
    "ts": null,
    "headline": "Review Preview: New Year, Same Bull",
    "summary": "Traders returned from a long break—and stocks resumed their 2025 ways. Plus, investors’ look past Venezuela.",
    "url": "https://finnhub.io/api/news?id=31ec70cf4fede99287dc1e97fdf9cc1b0c04d2379f572d8d591e93428cce3469",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767660900,
      "headline": "Review Preview: New Year, Same Bull",
      "id": 137997646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JPM",
      "source": "Yahoo",
      "summary": "Traders returned from a long break—and stocks resumed their 2025 ways. Plus, investors’ look past Venezuela.",
      "url": "https://finnhub.io/api/news?id=31ec70cf4fede99287dc1e97fdf9cc1b0c04d2379f572d8d591e93428cce3469"
    }
  }
]